Clinical Trial Update: A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR). [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of ciclesonide nasal aerosol in children 6-11 with perennial allergic rhinitis; results from the completed study hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perennial Allergic Rhinitis

Drugs mentioned

• Ciclesonide nasal aerosol (ciclesonide)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Perennial Allergic Rhinitis, PAR | Phase 3 | Status: COMPLETED | Results posted: 2014-05-06